New Perspectives of Therapies in Osteogenesis Imperfecta-A Literature Review

被引:9
作者
Dinulescu, Alexandru [1 ,2 ,3 ]
Pasarica, Alexandru-Sorin [3 ,4 ]
Carp, Madalina [1 ,2 ,3 ,4 ]
Dusca, Andrei [1 ,2 ,3 ,4 ]
Dijmarescu, Irina [1 ,2 ,3 ,4 ]
Pavelescu, Mirela Luminita [1 ,2 ,3 ,4 ]
Pacurar, Daniela [1 ,2 ,3 ,4 ]
Ulici, Alexandru [1 ,2 ,3 ,4 ]
机构
[1] Carol Davila Univ Med & Pharm, Dept Pediat, Bucharest 020021, Romania
[2] Carol Davila Univ Med & Pharm, Dept Pediat Orthoped, Bucharest 020021, Romania
[3] Emergency Hosp Children Grigore Alexandrescu, Dept Pediat, Bucharest 011743, Romania
[4] Emergency Hosp Children Grigore Alexandrescu, Dept Pediat Orthoped, Bucharest 011743, Romania
关键词
osteogenesis imperfecta; mesenchymal stem cells; sclerostin inhibition; anti-RANKL antibodies; gene therapy; recombinant PTH; anti-TGF-beta antibodies; inhibition of eIF2 alpha phosphatase enzymes; MESENCHYMAL STEM-CELLS; SCLEROSTIN ANTIBODY TREATMENT; BRTL/+ MOUSE MODEL; THERAPEUTIC APPROACH; BONE MASS; CHILDREN; DENOSUMAB; FETAL; IMPROVES; TRANSPLANTATION;
D O I
10.3390/jcm13041065
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
(1) Background: Osteogenesis imperfecta (OI) is a rare skeletal dysplasia characterized as a heterogeneous disorder group with well-defined phenotypic and genetic features that share uncommon bone fragility. The current treatment options, medical and orthopedic, are limited and not efficient enough to improve the low bone density, bone fragility, growth, and mobility of the affected individuals, creating the need for alternative therapeutic agents. (2) Methods: We searched the medical database to find papers regarding treatments for OI other than conventional ones. We included 45 publications. (3) Results: In reviewing the literature, eight new potential therapies for OI were identified, proving promising results in cells and animal models or in human practice, but further research is still needed. Bone marrow transplantation is a promising therapy in mice, adults, and children, decreasing the fracture rate with a beneficial effect on structural bone proprieties. Anti-RANKL antibodies generated controversial results related to the therapy schedule, from no change in the fracture rate to improvement in the bone mineral density resorption markers and bone formation, but with adverse effects related to hypercalcemia. Sclerostin inhibitors in murine models demonstrated an increase in the bone formation rate and trabecular cortical bone mass, and a few human studies showed an increase in biomarkers and BMD and the downregulation of resorption markers. Recombinant human parathormone and TGF-beta generated good results in human studies by increasing BMD, depending on the type of OI. Gene therapy, 4-phenylbutiric acid, and inhibition of eIF2 alpha phosphatase enzymes have only been studied in cell cultures and animal models, with promising results. (4) Conclusions: This paper focuses on eight potential therapies for OI, but there is not yet enough data for a new, generally accepted treatment. Most of them showed promising results, but further research is needed, especially in the pediatric field.
引用
收藏
页数:21
相关论文
共 98 条
[1]   Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome) [J].
Baljet, B .
ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER, 2002, 184 (01) :1-7
[2]   A systematic review and meta-analysis on the efficacy of stem cell therapy on bone brittleness in mouse models of osteogenesis imperfecta [J].
Battle, Lauren ;
Yakar, Shoshana ;
Carriero, Alessandra .
BONE REPORTS, 2021, 15
[3]  
Besio R, 2015, Adv. Regen. Biol, V2, P27964, DOI DOI 10.3402/ARB.V2.27964
[4]   4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion [J].
Besio, Roberta ;
Iula, Giusy ;
Garibaldi, Nadia ;
Cipolla, Lina ;
Sabbioneda, Simone ;
Biggiogera, Marco ;
Marini, Joan C. ;
Rossi, Antonio ;
Forlino, Antonella .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (05) :1642-1652
[5]  
Bobis S, 2006, FOLIA HISTOCHEM CYTO, V44, P215
[6]   Osteogenesis Imperfecta: Current and Prospective Therapies [J].
Botor, Malwina ;
Fus-Kujawa, Agnieszka ;
Uroczynska, Marta ;
Stepien, Karolina L. ;
Galicka, Anna ;
Gawron, Katarzyna ;
Sieron, Aleksander L. .
BIOMOLECULES, 2021, 11 (10)
[7]   Sclerostin antibody reduces long bone fractures in the oim/oim model of, Check for osteogenesis imperfecta [J].
Cardinal, Mickael ;
Tys, Janne ;
Roels, Thomas ;
Lafont, Sebastien ;
Ominsky, Michael S. ;
Devogelaer, Jean-Pierre ;
Chappard, Daniel ;
Mabilleau, Guillaume ;
Ammann, Patrick ;
Nyssen-Behets, Catherine ;
Manicourt, Daniel H. .
BONE, 2019, 124 :137-147
[8]   Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta [J].
Chamberlain, Joel R. ;
Deyle, David R. ;
Schwarze, Ulrike ;
Wang, Peirong ;
Hirata, Roli K. ;
Li, Yi ;
Byers, Peter H. ;
Russell, David W. .
MOLECULAR THERAPY, 2008, 16 (01) :187-193
[9]   Gene targeting in stem cells from individuals with osteogenesis imperfecta [J].
Chamberlain, JR ;
Schwarze, U ;
Wang, PR ;
Hirata, RK ;
Hankenson, KD ;
Pace, JM ;
Underwood, RA ;
Song, KM ;
Sussman, M ;
Byers, PH ;
Russell, DW .
SCIENCE, 2004, 303 (5661) :1198-1201
[10]   Serum Sclerostin and Its Association with Bone Turnover Marker in Metabolic Bone Diseases [J].
Chen, Lihui ;
Gao, Gao ;
Shen, Li ;
Yue, Hua ;
Zhang, Ge ;
Zhang, Zhenlin .
DISEASE MARKERS, 2022, 2022